Muscle derangement and alteration of the nutritional machinery in NSCLC.


Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 19 03 2019
revised: 08 06 2019
accepted: 09 06 2019
pubmed: 23 6 2019
medline: 18 10 2019
entrez: 23 6 2019
Statut: ppublish

Résumé

Weight loss and depletion of nutritional status are frequent presentation hallmarks in non-small cell lung cancer (NSCLC). Decline in muscle mass is a major component in weight loss and may have both a prognostic and predictive value for survival and treatment-related toxicities. Recent findings suggest that weight and skeletal muscle mass gain during treatment may represent surrogate markers for outcome in advanced NSCLC patients. Herein we present an in-depth view of the impact of nutritional status derangements on NSCLC patients' outcome, focusing on lean body mass variations during disease course. We explored the impact of malnutrition with a major attention on novel treatment options. We reviewed molecular, metabolic and immunological mechanisms underlying muscle-wasting condition, which may exhibit a meaningful targeting potential. Incorporating a specialized and accurate body composition assessment into a comprehensive, patient-centered and tailored intervention will facilitate the achievement of nutritional goals and optimal care for lung cancer patients.

Identifiants

pubmed: 31228648
pii: S1040-8428(19)30123-4
doi: 10.1016/j.critrevonc.2019.06.007
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-53

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ilaria Trestini (I)

Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: ilariatrestini@alice.it.

Anastasios Gkountakos (A)

Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy. Electronic address: anastasios.gkountakos@univr.it.

Luisa Carbognin (L)

Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Division of Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli, I.R.C.C.S., Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: luisa.carbognin@univr.it.

Alice Avancini (A)

Biomedical Sciences, Department of Medicine, University of Verona, Italy. Electronic address: alice.avancini@univr.it.

Massimo Lanza (M)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy. Electronic address: massimo.lanza@univr.it.

Alessio Molfino (A)

Department of Clinical Medicine, Sapienza University of Rome, Italy. Electronic address: alessio.molfino@uniroma1.it.

Simonetta Friso (S)

Department of Medicine, School of Medicine, University of Verona, Verona, Italy. Electronic address: simonetta.friso@univr.it.

Vincenzo Corbo (V)

Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy; ARC-NET, Applied Research on Cancer Center, University and Hospital Trust of Verona, Verona, Italy. Electronic address: vincenzo.corbo@univr.it.

Giampaolo Tortora (G)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica Del Sacro Cuore, Rome, Italy. Electronic address: giampaolo.tortora@unicatt.it.

Aldo Scarpa (A)

Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy; ARC-NET, Applied Research on Cancer Center, University and Hospital Trust of Verona, Verona, Italy. Electronic address: aldo.scarpa@univr.it.

Michele Milella (M)

Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: michele.milella@univr.it.

Emilio Bria (E)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica Del Sacro Cuore, Rome, Italy. Electronic address: emilio.bria@unicatt.it.

Sara Pilotto (S)

Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: sara.pilotto@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH